{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:31Z","timestamp":1790727031007,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1053\/j.ackd.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T19:01:34Z","timestamp":1555959694000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Resistant Hypertension: Diagnosis and Management"],"prefix":"10.1053","volume":"26","author":[{"given":"Nagalakshmi","family":"Nagarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1975-8650","authenticated-orcid":false,"given":"Diana","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Feb 23","key":"10.1053\/j.ackd.2019.03.002_bib1","first-page":"3","article-title":"Timeline of history of hypertension treatment","volume":"3","author":"Saklayen","year":"2016","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.0954-6820.1967.tb10882.x","article-title":"A clinical trial of guanoxan (Envacar) in hypertension resistant to common drugs","volume":"182","author":"Persson","year":"1967","journal-title":"Acta Med Scand"},{"issue":"4 suppl 3","key":"10.1053\/j.ackd.2019.03.002_bib3","first-page":"751","article-title":"Labetalol in resistant hypertension","volume":"3","author":"Dargie","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1053\/j.ackd.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"issue":"11","key":"10.1053\/j.ackd.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1097\/HJH.0b013e3282ef6185","article-title":"Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis","volume":"25","author":"Fagard","year":"2007","journal-title":"J Hypertens"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jch.12672","article-title":"Improvement in all-cause mortality with blood pressure control in a group of US Veterans with drug-resistant hypertension","volume":"18","author":"Fatemi","year":"2016","journal-title":"J Clin Hypertens"},{"issue":"25","key":"10.1053\/j.ackd.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1053\/j.ackd.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/HYPERTENSIONAHA.116.06587","article-title":"Refractory hypertension: a novel phenotype of antihypertensive treatment failure","volume":"67","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"issue":"10","key":"10.1053\/j.ackd.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","article-title":"Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system","volume":"88","author":"Sim","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"10.1053\/j.ackd.2019.03.002_bib11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(18)30080-9","article-title":"Fluid retention, aldosterone excess, and treatment of resistant hypertension","volume":"6","author":"Calhoun","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: comparing hemodynamic management to specialist care","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","article-title":"Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure","volume":"66","author":"Dudenbostel","year":"2015","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MBP.0000000000000349","article-title":"Mean mid-arm circumference and blood pressure cuff sizes for US children, adolescents and adults: National Health and Nutrition Examination Survey, 2011-2016","volume":"23","author":"Ostchega","year":"2018","journal-title":"Blood Press Monit"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib16","first-page":"158","article-title":"White coat effect and white coat hypertension: one and the same?","volume":"3","author":"Ramli","year":"2008","journal-title":"Malays Fam Physician"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/euhj.2001.2657","article-title":"Properly defining white coat hypertension","volume":"23","author":"Verdecchia","year":"2002","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jash.2013.06.004","article-title":"Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence","volume":"7","author":"Grigoryan","year":"2013","journal-title":"J Am Soc Hypertens"},{"issue":"11","key":"10.1053\/j.ackd.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/jch.12896","article-title":"True resistant hypertension following observed drug ingestion: a systematic evaluation","volume":"19","author":"Bunker","year":"2017","journal-title":"J Clin Hypertens"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens"},{"issue":"Apr 3","key":"10.1053\/j.ackd.2019.03.002_bib22","doi-asserted-by":"crossref","first-page":"f1325","DOI":"10.1136\/bmj.f1325","article-title":"Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials","volume":"346","author":"He","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"10.1053\/j.ackd.2019.03.002_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11906-016-0682-1","article-title":"Common substances that may contribute to resistant hypertension, and recommendations for limiting their clinical effects","volume":"18","author":"Jurca","year":"2016","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2011.05.024","article-title":"Drug-induced hypertension: an unappreciated cause of secondary hypertension","volume":"125","author":"Grossman","year":"2012","journal-title":"Am J Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4330\/wjc.v6.i5.245","article-title":"Alcohol-induced hypertension: mechanism and prevention","volume":"6","author":"Husain","year":"2014","journal-title":"World J Cardiol"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib26","first-page":"37","article-title":"Substance abuse and hypertension","volume":"2","author":"Ferdinand","year":"2000","journal-title":"J Clin Hypertens"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2007.01.119","article-title":"Secondary hypertension: current diagnosis and treatment","volume":"124","author":"Chiong","year":"2008","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1053\/j.ackd.2019.03.002_bib28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients","volume":"59","author":"Thase","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1081\/JDI-120022548","article-title":"Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients","volume":"25","author":"Shimada","year":"2003","journal-title":"Ren Fail"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0002-9378(76)90480-4","article-title":"Oral contraceptives\u2014induced hypertension\u2014nine years later","volume":"126","author":"Laragh","year":"1976","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1053\/j.ackd.2019.03.002_bib32","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","article-title":"High prevalence of unrecognized sleep apnoea in drug-resistant hypertension","volume":"19","author":"Logan","year":"2001","journal-title":"J Hypertens"},{"issue":"19","key":"10.1053\/j.ackd.2019.03.002_bib33","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200005113421901","article-title":"Prospective study of the association between sleep-disordered breathing and hypertension","volume":"342","author":"Peppard","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","article-title":"Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension","volume":"58","author":"Pedrosa","year":"2011","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2019.03.002_bib35","doi-asserted-by":"crossref","first-page":"340929","DOI":"10.4061\/2011\/340929","article-title":"Resistant hypertension and obstructive sleep apnea in the primary-care setting","volume":"2011","author":"Demede","year":"2011","journal-title":"Int J Hypertens"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","article-title":"Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"issue":"24","key":"10.1053\/j.ackd.2019.03.002_bib37","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","article-title":"Human adipocytes secrete mineralocorticoid-releasing factors","volume":"100","author":"Ehrhart-Bornstein","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11906-016-0641-x","article-title":"Resistant hypertension and chronic kidney disease: a dangerous liaison","volume":"18","author":"Wolley","year":"2016","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"10.1053\/j.ackd.2019.03.002_bib39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00004872-199208000-00002","article-title":"Hypertension in human renal disease","volume":"10","author":"Brown","year":"1992","journal-title":"J Hypertens"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib40","first-page":"155","article-title":"Pathogenesis of hypertension in chronic renal disease","volume":"8","author":"Kincaid-Smith","year":"1988","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.ackd.2014.12.001","article-title":"Management of hypertension in CKD: beyond the guidelines","volume":"22","author":"Judd","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib42","first-page":"74","article-title":"Renin-angiotensin system and blood volume in patients with dialysis-resistant hypertension","volume":"23","author":"Huysmans","year":"1980","journal-title":"Neth J Med"},{"issue":"20","key":"10.1053\/j.ackd.2019.03.002_bib43","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2019.03.002_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3317\/jraas.2000.062","article-title":"The losartan renal protection study\u2014rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)","volume":"1","author":"Brenner","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"9628","key":"10.1053\/j.ackd.2019.03.002_bib46","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"Douma","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2019.03.002_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7030-8_1","article-title":"A brief introduction into the renin-angiotensin-aldosterone system: new and old techniques","volume":"1614","author":"Thatcher","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib48","first-page":"394","article-title":"The aldosterone\/renin ratio as a screening test for primary aldosteronism","volume":"90","author":"Rayner","year":"2000","journal-title":"S Afr Med J"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib50","first-page":"39","article-title":"Laboratory investigation of primary aldosteronism","volume":"31","author":"Stowasser","year":"2010","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib51","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.HYP.6.5.717","article-title":"Further evaluation of saline infusion for the diagnosis of primary aldosteronism","volume":"6","author":"Holland","year":"1984","journal-title":"Hypertension"},{"issue":"18","key":"10.1053\/j.ackd.2019.03.002_bib52","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.1993.00410180075008","article-title":"The diagnosis of primary aldosteronism and separation of two major subtypes","volume":"153","author":"Weinberger","year":"1993","journal-title":"Arch Intern Med"},{"issue":"25","key":"10.1053\/j.ackd.2019.03.002_bib53","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199812173392507","article-title":"Primary aldosteronism","volume":"339","author":"Ganguly","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib54","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000184411","article-title":"A renin-secreting tumor","volume":"46","author":"Pedrinelli","year":"1987","journal-title":"Nephron"},{"issue":"12","key":"10.1053\/j.ackd.2019.03.002_bib55","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/hrt.40.12.1415","article-title":"Plasma renin activity in coarctation of the aorta before and after surgical correction","volume":"40","author":"Fallo","year":"1978","journal-title":"Br Heart J"},{"issue":"11","key":"10.1053\/j.ackd.2019.03.002_bib56","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ajh.2010.174","article-title":"Renovascular hypertension and ischemic nephropathy","volume":"23","author":"Textor","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2019.03.002_bib57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev.me.35.020184.003313","article-title":"Renovascular hypertension","volume":"35","author":"Treadway","year":"1984","journal-title":"Annu Rev Med"},{"issue":"May 13","key":"10.1053\/j.ackd.2019.03.002_bib58","first-page":"169","article-title":"Renal artery stenosis: epidemiology and treatment","volume":"7","author":"Weber","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib59","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.1987.00370050016004","article-title":"Detection, evaluation, and treatment of renovascular hypertension. Final report. Working Group on Renovascular Hypertension","volume":"147","year":"1987","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJM200102083440607","article-title":"Renal-artery stenosis","volume":"344","author":"Safian","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib61","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJM197507312930502","article-title":"Measures of clinical efficacy. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease","volume":"293","author":"McNeil","year":"1975","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-135-6-200109180-00009","article-title":"Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis","volume":"135","author":"Vasbinder","year":"2001","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1053\/j.ackd.2019.03.002_bib63","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJM199109263251309","article-title":"Differential diagnosis of Cushing's syndrome","volume":"325","author":"Orth","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.03.002_bib64","series-title":"Renal and Electrolyte Disorders","article-title":"The kidney in hypertension","author":"Jalal","year":"2016"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11906-005-0013-4","article-title":"Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management","volume":"7","author":"Sacerdote","year":"2005","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib66","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1751-7176.2008.07470.x","article-title":"Pseudohyperaldosteronism, liquorice, and hypertension","volume":"10","author":"Sontia","year":"2008","journal-title":"J Clin Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib68","first-page":"505","article-title":"Adverse effects of corticosteroids on the cardiovascular system","volume":"16","author":"Sholter","year":"2000","journal-title":"Can J Cardiol"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib69","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00000441-200112000-00002","article-title":"Liddle syndrome: genetics and mechanisms of Na+ channel defects","volume":"322","author":"Warnock","year":"2001","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib70","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4103\/2230-8210.100665","article-title":"Low renin hypertension","volume":"16","author":"Sahay","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib72","first-page":"354","article-title":"Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series","volume":"56","author":"Sutton","year":"1981","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.ackd.2019.03.002_bib73","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijscr.2018.08.019","article-title":"Anaesthetic management of cardiac phaeochromocytoma: a case series","volume":"51","author":"Chen","year":"2018","journal-title":"Int J Surg Case Rep"},{"issue":"11","key":"10.1053\/j.ackd.2019.03.002_bib74","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"16","key":"10.1053\/j.ackd.2019.03.002_bib75","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group","volume":"336","author":"Appel","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","article-title":"Effects of the DASH diet\u00a0alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study","volume":"170","author":"Blumenthal","year":"2010","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib77","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/HYPERTENSIONAHA.109.149153","article-title":"Effects of the dietary approaches to stop hypertension diet\u00a0alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids","volume":"55","author":"Blumenthal","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib79","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1524-6175.2007.06112.x","article-title":"Explicit and implicit evaluation of physician adherence to hypertension guidelines","volume":"9","author":"Ardery","year":"2007","journal-title":"J Clin Hypertens"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pec.2008.01.021","article-title":"Physician counseling for hypertension: what do doctors really do?","volume":"72","author":"Bell","year":"2008","journal-title":"Patient Educ Couns"},{"issue":"Feb 1","key":"10.1053\/j.ackd.2019.03.002_bib81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2296-11-8","article-title":"Patient recall of receiving lifestyle advice for overweight and hypertension from their General Practitioner","volume":"11","author":"Booth","year":"2010","journal-title":"BMC Fam Pract"},{"issue":"9","key":"10.1053\/j.ackd.2019.03.002_bib82","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1525-1497.2004.30355.x","article-title":"Prevalence of nutrition and exercise counseling for patients with hypertension. United States, 1999 to 2000","volume":"19","author":"Mellen","year":"2004","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib83","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11606-014-3059-7","article-title":"Documented lifestyle education among young adults with incident hypertension","volume":"30","author":"Johnson","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40119-016-0079-x","article-title":"Knowledge of hypertension and compliance with therapy among hypertensive patients in the Bamenda health district of Cameroon: a cross-sectional study","volume":"6","author":"Akoko","year":"2017","journal-title":"Cardiol Ther"},{"issue":"10","key":"10.1053\/j.ackd.2019.03.002_bib85","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/HJH.0b013e32833b9c63","article-title":"Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial","volume":"28","author":"Lozano","year":"2010","journal-title":"J Hypertens"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib86","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jch.12639","article-title":"Continuous positive airway pressure in patients with obstructive sleep apnea and resistant hypertension: a meta-analysis of randomized controlled trials","volume":"18","author":"Liu","year":"2016","journal-title":"J Clin Hypertens (Greenwich, Conn)"},{"issue":"8","key":"10.1053\/j.ackd.2019.03.002_bib87","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/HJH.0000000000000238","article-title":"A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea","volume":"32","author":"Lloberes","year":"2014","journal-title":"J Hypertens"},{"issue":"8","key":"10.1053\/j.ackd.2019.03.002_bib88","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens"},{"issue":"12","key":"10.1053\/j.ackd.2019.03.002_bib89","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized trial of dietary sodium restriction in CKD","volume":"24","author":"McMahon","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib90","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1152\/ajprenal.00119.2002","article-title":"Loop diuretics: from the Na-K-2Cl transporter to clinical use","volume":"284","author":"Shankar","year":"2003","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich, Conn)"},{"issue":"21","key":"10.1053\/j.ackd.2019.03.002_bib92","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib93","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"issue":"5 suppl 1","key":"10.1053\/j.ackd.2019.03.002_bib94","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"9069","key":"10.1053\/j.ackd.2019.03.002_bib95","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"15","key":"10.1053\/j.ackd.2019.03.002_bib96","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ackd.2019.03.002_bib97","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1245\/s10434-013-2871-3","article-title":"Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes","volume":"20","author":"Kline","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00423-014-1269-4","article-title":"Outcome of surgical treatment of primary aldosteronism","volume":"400","author":"Citton","year":"2015","journal-title":"Langenbecks Arch Surg"},{"issue":"20","key":"10.1053\/j.ackd.2019.03.002_bib99","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis","volume":"361","author":"Investigators","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2019.03.002_bib100","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-150-12-200906160-00119","article-title":"Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial","volume":"150","author":"Bax","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal-artery stenosis","volume":"370","author":"Cooper","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.ackd.2019.03.002_bib102","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2015.09.072","article-title":"The CORAL trial, round 2","volume":"66","author":"Gafoor","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib103","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0025-6196(11)64210-9","article-title":"Outcomes of atherosclerotic renal artery stenosis managed without revascularization","volume":"75","author":"Chabova","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1053\/j.ackd.2019.03.002_bib104","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199503233321207","article-title":"Cushing's syndrome","volume":"332","author":"Orth","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.03.002_bib105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM197107292850501","article-title":"Results of treatment in 108 patients with Cushing's syndrome","volume":"285","author":"Orth","year":"1971","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib106","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib107","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib108","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM199701163360303","article-title":"The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease","volume":"336","author":"Estrada","year":"1997","journal-title":"N Engl J Med"},{"issue":"Pt A","key":"10.1053\/j.ackd.2019.03.002_bib109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jsbmb.2016.02.014","article-title":"Apparent mineralocorticoid excess and the long term treatment of genetic\u00a0hypertension","volume":"165","author":"Razzaghy-Azar","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"10.1053\/j.ackd.2019.03.002_bib110","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archsurg.2010.159","article-title":"One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy","volume":"145","author":"Shen","year":"2010","journal-title":"Arch Surg"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib111","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib112","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib113","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/HYPERTENSIONAHA.112.192096","article-title":"The association between\u00a0medication adherence and treatment intensification with blood pressure control in resistant hypertension","volume":"60","author":"Daugherty","year":"2012","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib114","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11886-002-0110-9","article-title":"Vasodilatory edema: a common side effect of antihypertensive therapy","volume":"4","author":"Messerli","year":"2002","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib115","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/HYPERTENSIONAHA.111.180497","article-title":"Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents","volume":"58","author":"Hanselin","year":"2011","journal-title":"Hypertension"},{"issue":"3","key":"10.1053\/j.ackd.2019.03.002_bib116","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"issue":"Jul 30","key":"10.1053\/j.ackd.2019.03.002_bib117","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/IBPC.S40248","article-title":"Which thiazide to choose as add-on therapy for hypertension?","volume":"7","author":"Barrios","year":"2014","journal-title":"Integr Blood Press Control"},{"issue":"943","key":"10.1053\/j.ackd.2019.03.002_bib118","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/pgmj.2003.010843","article-title":"Use of diuretics in cardiovascular disease: (2) hypertension","volume":"80","author":"Shah","year":"2004","journal-title":"Postgrad Med J"},{"issue":"10008","key":"10.1053\/j.ackd.2019.03.002_bib119","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"11 Pt 1","key":"10.1053\/j.ackd.2019.03.002_bib120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2019.03.002_bib121","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1053\/j.ackd.2019.03.002_bib122","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jash.2015.03.002","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"9","author":"Rosendorff","year":"2015","journal-title":"J Am Soc Hypertens"},{"issue":"21","key":"10.1053\/j.ackd.2019.03.002_bib123","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.110.012781","article-title":"Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions","volume":"123","author":"Cole","year":"2011","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2019.03.002_bib124","series-title":"Minoxidil","author":"Badri","year":"2018"},{"issue":"1","key":"10.1053\/j.ackd.2019.03.002_bib125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.1981.128","article-title":"Minoxidil and pericardial effusion: an idiosyncratic reaction","volume":"30","author":"Reichgott","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"10.1053\/j.ackd.2019.03.002_bib126","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"issue":"9981","key":"10.1053\/j.ackd.2019.03.002_bib127","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ackd.2019.03.002_bib128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCRESAHA.115.304099","article-title":"Renal denervation and Symplicity HTN-3: \u201cDubium sapientiae initium\u201d (doubt is the beginning of wisdom)","volume":"115","author":"Papademetriou","year":"2014","journal-title":"Circ Res"},{"issue":"7","key":"10.1053\/j.ackd.2019.03.002_bib129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519300333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519300333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:02:00Z","timestamp":1761548520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519300333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":129,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1548559519300333"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.03.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant Hypertension: Diagnosis and Management","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}